GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tiziana Life Sciences
Tiziana Life Sciences is a biotech company developing drugs for the treatment of autoimmune diseases and cancer. Its stock price is highly volatile, driven by news of clinical trials of its innovative approaches, such as oral antibody delivery.
Share prices of companies in the market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing drugs for the treatment of inflammatory, autoimmune, and oncological diseases. We have classified it in the Pharma: Immunology group. The chart below shows how investors value companies with a broad pipeline.
Broad Market Index - GURU.Markets
Tiziana Life Sciences is a biotech company developing drugs to treat inflammatory, autoimmune, and oncological diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TLSA - Daily change in the company's share price Tiziana Life Sciences
The daily fluctuations of Tiziana, a biopharmaceutical company, reflect the inherent volatility of the sector. change_co measures the reaction to research data and regulatory decisions. This metric is important for analyzing risks and opportunities in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Tiziana Life Sciences Ltd is a biotech company. This chart highlights the sector's extreme volatility. Comparison with TLSA, which focuses on immunology, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow, shaping its daily pattern.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tiziana Life Sciences
For Tiziana Life Sciences, the year-over-year trend is a story of developing oral and nasal immunomodulators. Its 12-month market cap depends entirely on clinical trial data. The success of its injection-free approach could lead to a breakthrough in the treatment of diseases such as Crohn's disease and multiple sclerosis.
Annual dynamics of market capitalization of the market segment - Pharma immune
Tiziana Life Sciences Ltd. is a biotechnology company developing innovative drugs for the treatment of inflammatory diseases and cancer. Its unique oral antibody delivery technology is a key advantage. Its stock price reflects the high potential of its scientific platform and the risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tiziana is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tiziana Life Sciences
The performance of Tiziana, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for multiple sclerosis and other diseases, based on its unique oral delivery technology.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing drugs to treat immunology and oncology diseases. Like many companies in the sector, its value depends on progress in clinical trials. The industry's performance on the chart is a barometer of investor sentiment toward risky scientific developments, where Tiziana is seeking its breakthrough.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tiziana Life Sciences Ltd. is a biotech company developing innovative treatments for inflammatory diseases and oncology. The company's future depends solely on the success of its clinical trials. The broader market chart serves only as a contrasting backdrop to understand how news about its drugs, including nasal therapy, impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tiziana Life Sciences
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat immune diseases. Its weekly stock price, like that of many biotech companies, is extremely volatile and depends on news about clinical trials of its innovative approaches, such as a nasal spray.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat immune system disorders. Its shares are extremely sensitive to clinical trial news. The chart clearly demonstrates how its weekly performance is unique and independent of general pharmaceutical industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tiziana is a clinical-stage biotech company. Its shares are trading in anticipation of trial results. The chart clearly shows how much their performance is driven by scientific news and regulatory decisions, rather than by general market trends.
Market capitalization of the company, segment and market as a whole
TLSA - Market capitalization of the company Tiziana Life Sciences
Tiziana Life Sciences' market capitalization is volatile, reflecting the biotech company's development of innovative oral immunotherapy treatments. Its valuation is driven by news of clinical trials of its drugs for conditions such as Crohn's disease and multiple sclerosis.
TLSA - Share of the company's market capitalization Tiziana Life Sciences within the market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing innovative drugs for the treatment of autoimmune diseases and oncology. Its market share reflects the potential of its platform. Its market capitalization chart is a venture capital story, full of hope that its unique treatment approaches will yield results.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. Tiziana Life Sciences is a company developing innovative approaches to treating immune diseases, including nasal sprays. The dynamics of this market are full of stories of breakthroughs and failures. Tiziana is striving to prove that its unique delivery methods can be a game-changer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tiziana Life Sciences develops innovative drugs for the treatment of autoimmune diseases and oncology using nasal and oral delivery. Its market cap is driven by a focus on more convenient therapies. The chart below shows the weightings of biotech companies with new platforms.
Book value capitalization of the company, segment and market as a whole
TLSA - Book value capitalization of the company Tiziana Life Sciences
Tiziana Life Sciences' foundation is its intellectual property in drugs for treating immune diseases, specifically an antibody-based nasal spray. The book value represents the capital it uses to conduct clinical trials. The graph tells the story of a biotech company developing innovative drug delivery methods for the treatment of complex diseases.
TLSA - Share of the company's book capitalization Tiziana Life Sciences within the market segment - Pharma immune
Tiziana Life Sciences develops innovative drug delivery methods. The chart shows its share of actual R&D assets. These are its laboratories where technologies are created for the oral and nasal administration of drugs that typically require injections.
Market segment balance sheet capitalization - Pharma immune
Tiziana Life Sciences is a biotech company whose value is locked into its scientific platform. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which underscores its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat diseases in the fields of immunology and oncology. Its assets are its scientific developments. A modest stake in BCap_All is a material resource aimed at developing innovative treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tiziana Life Sciences
Tiziana Life Sciences is a biopharmaceutical company. Its market capitalization is a premium to its cash flow, reflecting its unique approaches to treating autoimmune diseases and cancer with oral and nasal medications.
Market to book capitalization ratio in a market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases. Its value is based almost entirely on its scientific potential. The chart shows the huge premium to book value that investors are paying for the hope of developing breakthrough drugs.
Market to book capitalization ratio for the market as a whole
Tiziana Life Sciences is a biotech company developing drugs to treat inflammatory diseases. Its valuation depends almost entirely on the success of clinical trials. This chart demonstrates how market value in biotech can be detached from book value, reflecting expectations for future drugs.
Debts of the company, segment and market as a whole
TLSA - Company debts Tiziana Life Sciences
Tiziana Life Sciences, a biotech company developing drugs to treat immune diseases, uses capital to fund its clinical programs. Its debt strategy is focused on advancing innovative approaches, such as oral antibody delivery, which require expensive and time-consuming proof-of-concept studies.
Market segment debts - Pharma immune
Tiziana Life Sciences is a biotechnology company developing drugs to treat diseases in the fields of immunology and oncology. Its approach includes the development of oral and nasal drugs. This chart shows the financial model the company uses to fund its innovative, yet expensive, clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tiziana Life Sciences
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat immunology and oncology diseases. Clinical trials require significant investment. This chart demonstrates the company's reliance on debt to finance R&D, allowing one to assess its financial risks before a product reaches market.
Market segment debt to market segment book capitalization - Pharma immune
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases. The chart shows debt trends in their sector. For a company exploring innovative approaches such as oral antibody delivery, this allows them to assess how they finance their long-term and risky clinical programs.
Debt to book value of all companies in the market
Tiziana Life Sciences is a biopharmaceutical company developing treatments for oncology and immune diseases. Its research and development activities are financed through equity capital, as the company lacks the revenue to service its debt. This chart of overall market leverage clearly demonstrates the financial gap between innovative biotech and the traditional economy.
P/E of the company, segment and market as a whole
P/E - Tiziana Life Sciences
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory diseases and oncology. This chart shows that the company's valuation is based on the potential of its scientific developments, not current revenue. Investors are betting on the success of clinical trials of its unique therapeutic approaches.
P/E of the market segment - Pharma immune
This industry chart for biotech companies provides key context for Tiziana Life Sciences. It reflects overall high valuations based on breakthrough expectations. Comparisons with this chart help understand whether Tiziana's innovative approach to oral and nasal antibody delivery for autoimmune diseases is considered more promising than its competitors.
P/E of the market as a whole
Tiziana Life Sciences is a biotech company with a broad pipeline in immunology. It uses innovative drug delivery methods, such as nasal delivery. This chart of overall biotech risk appetite shows how much investors are willing to trust companies with a platform approach and multiple early-stage projects, but without a clear leader.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company developing drugs for the treatment of immune diseases and oncology. This chart reflects speculative expectations for its scientific platform. The valuation depends on progress in clinical trials of its candidates, particularly their innovative drug delivery approach, and confidence in their future commercial success.
%20P%2FE%20Tiziana%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tiziana-Life-Sciences&v=1772696280932 "Chart of the company's future (projected) P/E Tiziana Life Sciences")
Future (projected) P/E of the market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing innovative treatments for inflammatory diseases and oncology. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into the market's confidence in its scientific developments, including nasal therapies for COVID-19 and multiple sclerosis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772696280933 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Tiziana Life Sciences is a biotech company developing innovative treatments for inflammatory and oncological diseases, including nasal therapies. For a clinical-stage company like Tiziana, this market sentiment chart is important. A bullish market facilitates raising the capital needed to conduct expensive and lengthy trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772696280939 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company developing innovative treatments for inflammatory and oncological diseases, including oral antibody delivery. This chart shows the financial expenditures on clinical trials and the development of potentially breakthrough therapeutic approaches.
Profit of companies in the market segment - Pharma immune
Tiziana Life Sciences is a biotechnology company developing drugs to treat immune diseases and cancer. This chart shows profitability in the immunology sector. For TLSA, this provides market context for their innovative approaches, including oral and nasal drug formulations, which could transform the treatment of complex diseases.
Overall market profit
Tiziana Life Sciences is a biotech company developing innovative treatments for inflammatory and oncological diseases, including oral antibody delivery. This is cutting-edge science, and the company's success depends on clinical data. The overall economic trends visible in this chart are secondary to the potential of its scientific platform.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company developing innovative treatments for inflammatory diseases and oncology, including oral immunotherapy. The revenue projections presented here are speculative and depend entirely on the success of its candidates in clinical trials, particularly Foralumab.
%20profit%20of%20the%20company%20Tiziana%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tiziana-Life-Sciences&v=1772696280985 "Graph of future (projected) profit of the company Tiziana Life Sciences")
Future (predicted) profit of companies in the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat immune diseases using innovative delivery methods, such as nasal delivery. The profit forecast for this sector depends on the clinical success of these new approaches. This chart reflects analysts' confidence in the potential of non-invasive treatments for complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772696281013 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Tiziana Life Sciences is a biopharmaceutical company developing drugs to treat immune diseases. Its value is determined by progress in clinical trials. Market-wide profit forecasts, reflected here, shape the investment climate, which affects the company's ability to attract R&D funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772696281024 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tiziana Life Sciences
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases and cancer. This chart shows a speculative valuation. The company is researching innovative drug delivery methods, and investors are betting on the potential breakthrough of its scientific platform rather than current financial results.
P/S market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing innovative treatments for inflammatory and oncological diseases, including oral antibody delivery. This chart reflects the average revenue estimate for the sector, providing insight into investor expectations for Tiziana's breakthrough scientific platform and clinical development.
P/S of the market as a whole
Tiziana Life Sciences is a biotech company developing innovative treatments for inflammatory and autoimmune diseases, as well as cancer, using oral and nasal medications. Success depends on clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company developing innovative treatments for inflammatory and autoimmune diseases, as well as cancer. This chart shows how investors estimate the company's future revenue potential based on its scientific developments and clinical data.
%20P%2FS%20Tiziana%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tiziana-Life-Sciences&v=1772696281124 "The graph of the company's future (projected) P/S Tiziana Life Sciences")
Future (projected) P/S of the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory diseases and cancer, including oral and nasal medications. This chart reflects the market's appreciation of its unique drug delivery approaches and the potential of its research and development pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772696281143 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases. As a clinical-stage company, it depends on research results and funding. This market optimism chart is important for TLSA. Investors' risk appetite, which is essential for biotech financing, is directly linked to the overall state of the economy and confidence in the future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772696281161 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biotechnology company developing innovative treatments for immune diseases and cancer. Currently, the company has no commercial products and its revenue is minimal. This timeline will determine whether the company can translate its scientific advances into commercially successful drugs.
Sales of companies in the market segment - Pharma immune
Tiziana Life Sciences is a biotechnology company developing innovative treatments for immune diseases and cancer. Their focus is on non-injectable drug delivery methods, such as oral and nasal sprays. While in clinical trials, the company does not yet have any commercial revenue from product sales.
Overall market sales
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory and autoimmune diseases, including Crohn's disease and multiple sclerosis. Its approach is based on oral and nasal antibody delivery. This revenue chart includes the healthcare sector, where TLSA is working to create more convenient and effective therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tiziana Life Sciences
Tiziana Life Sciences is a biotech company developing drugs to treat immune diseases, specifically multiple sclerosis. Its key development is a nasal spray that can modulate the immune response. This graph reflects analysts' expectations for the success of this innovative therapy in clinical trials.
%20sales%20of%20the%20company%20Tiziana%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tiziana-Life-Sciences&v=1772696281253 "Schedule of future (projected) sales of the company Tiziana Life Sciences")
Future (projected) sales of companies in the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory and oncological diseases, including nasal medications. This chart shows forecasts for the company's markets, such as Crohn's disease, and highlights the potential of new drug delivery methods to improve therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772696281263 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Tiziana Life Sciences, which develops drugs to treat autoimmune diseases and oncology, sees this chart as a reflection of the biotech investment climate. The stable economic growth projected here provides the capital needed to conduct clinical trials of the innovative drug delivery methods Tiziana is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772696281285 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tiziana Life Sciences
Tiziana Life Sciences is a biopharmaceutical company developing therapies for immune diseases and cancer. Being in clinical trials, its financial picture is characterized by a lack of revenue and significant R&D expenses. This chart shows the capital burn rate on the path to developing potentially breakthrough drugs.
Market segment marginality - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory diseases and cancer, including nasal medications. This graph reflects the potential of its scientific platform. A future strong result will confirm the success of its unique therapeutic approaches.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biotechnology company developing innovative treatments for immune diseases and cancer. Its distinctive feature is its focus on new drug delivery methods, such as intranasal delivery. This graphic shows a small team of scientists working to make therapy more effective and convenient for patients.
Share of the company's employees Tiziana Life Sciences within the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory and oncological diseases using nasal and oral drug delivery. This cutting-edge science requires a team of highly qualified researchers. This graph reflects its research intensity and talent concentration in the field of developing new drug delivery systems.
Number of employees in the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing innovative treatments for inflammatory diseases and oncology, including oral and nasal medications. This graphic shows a team of scientists exploring new, less invasive ways to deliver complex drugs to combat serious diseases.
Number of employees in the market as a whole
Tiziana Life Sciences is a biotechnology company developing drugs to treat diseases in the fields of immunology and oncology. A stable economic environment, reflected in the employment chart, is critical to their long-term success. It facilitates the attraction of investment capital necessary for conducting expensive clinical trials and bringing new treatments to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tiziana Life Sciences (TLSA)
Tiziana Life Sciences is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases and oncology. This chart, like that of many biotech companies, reflects investor expectations. The company's huge market capitalization per employee demonstrates that the market highly values its scientific platform and the potential for future drugs.
%20of%20the%20company%20Tiziana%20Life%20Sciences%20(TLSA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tiziana-Life-Sciences-TLSA&v=1772696281690 "Chart of market capitalization per employee (in thousands of dollars) of the company Tiziana Life Sciences (TLSA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Tiziana Life Sciences is a biopharmaceutical company developing treatments for diseases in the fields of immunology and oncology. Its value is based on its research potential. This chart shows the market's valuation of its intellectual capital per employee, a key metric for research-stage biotech companies.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772696281709 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Tiziana Life Sciences is a biotech company developing new treatments for inflammatory diseases and cancer, including nasal drug delivery. This metric reflects the potential of its innovative approaches and demonstrates how the market values its science, which could offer new, less invasive treatment options.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772696281710 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tiziana Life Sciences (TLSA)
Tiziana Life Sciences is a clinical-stage biotech company developing drugs to treat immune diseases, including Crohn's disease. This company, like other biotech companies, is negative. All capital is spent on R&D and clinical trials. The research staff does not generate revenue but works on developing future drugs.
%20Chart%20Tiziana%20Life%20Sciences%20(TLSA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tiziana-Life-Sciences-TLSA&v=1772696281724 "Company Profit Per Employee (in thousands of dollars) Chart Tiziana Life Sciences (TLSA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Tiziana Life Sciences is a biotech company developing innovative therapies (often nasal or oral) for immune and inflammatory diseases, including Crohn's disease and Covid-19. This chart shows the industry benchmark, serving as a profitability benchmark for R&D companies. For Tiziana, it contrasts with the current research costs of their breakthrough platforms.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772696281735 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Tiziana Life Sciences is a biotech company developing drugs for the treatment of autoimmune and inflammatory diseases, including Crohn's disease and multiple sclerosis. Their focus is on the oral delivery (in tablets) of complex drugs. This is R&D. The chart shows the R&D investment (negative return) per scientist in the effort to develop these innovative treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772696281754 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tiziana Life Sciences (TLSA)
Tiziana Life Sciences is a biotechnology company developing drugs to treat diseases in the fields of immunology and oncology. This graph reflects the clinical trial stage. Potentially high revenue per employee in the future will result from the successful commercialization of its innovative treatment approaches, such as nasal sprays.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tiziana-Life-Sciences-TLSA&v=1772696281768 "Sales chart per company employee Tiziana Life Sciences (TLSA)")
Sales per employee in the market segment - Pharma immune
Tiziana Life Sciences is a clinical-stage biotech company developing drugs for the treatment of autoimmune diseases and oncology. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Tiziana Life Sciences is a biotech company developing innovative treatments for immune diseases and cancer. Their specialty is the oral delivery of complex drugs in tablets. This is a pure R&D business. This graph will likely show zero revenue, as their research team is still in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Tiziana Life Sciences (TLSA)
Tiziana Life Sciences (TLSA) is a biotech company developing drugs to treat immune diseases (such as multiple sclerosis) using innovative delivery methods, such as nasal delivery. This chart shows bearish bets. The high short interest reflects investor skepticism about their unconventional delivery methods and early clinical development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tiziana-Life-Sciences-TLSA&v=1772696281806 "Short Shares Chart for the Company Tiziana Life Sciences (TLSA)")
Shares shorted by market segment - Pharma immune
Tiziana (TLSA) is a biotech company developing drugs to treat inflammatory and autoimmune diseases, including Crohn's disease and multiple sclerosis. This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
Tiziana Life Sciences is a clinical-stage biotech developing treatments for immune diseases. Its value is based on its scientific potential. When market fear (as shown in this chart) is high, investors avoid speculative, non-revenue companies. This makes raising funds for R&D extremely challenging for biotech companies.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tiziana Life Sciences (TLSA)
Tiziana Life Sciences (TLSA) is a biotech company developing innovative treatments (including intranasal therapies) for autoimmune and inflammatory diseases, such as multiple sclerosis. This chart measures hype. It shows "overheated" (above 70) due to positive R&D data or "oversold" (below 30) amid delays or share price dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tiziana-Life-Sciences-TLSA&v=1772696281833 "RSI 14 indicator chart for the company's stock Tiziana Life Sciences (TLSA)")
RSI 14 Market Segment - Pharma immune
Tiziana (TLSA) is a biotech company developing drugs to treat immune diseases, including multiple sclerosis. They became known for developing a nasal spray. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether TLSA's performance reflects their trials or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
Tiziana Life Sciences (TLSA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TLSA (Tiziana Life Sciences)
Tiziana Life Sciences is a biotech company developing innovative treatments for immune diseases. Its key asset is an intranasal spray (Foralumab) for the treatment of multiple sclerosis. This chart shows the speculative average price target from analysts based on the potential of this R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TLSA-Tiziana-Life-Sciences&v=1772696281898 "A chart showing analyst consensus forecasts for the expected stock price. TLSA (Tiziana Life Sciences)")
The difference between the consensus estimate and the actual stock price TLSA (Tiziana Life Sciences)
Tiziana Life Sciences is a biotech company developing drugs for the treatment of inflammatory and autoimmune diseases (Crohn's disease, multiple sclerosis). Their specialty is the oral delivery (tablets) of large molecules (antibodies). This chart reflects analysts' speculative expectations regarding their R&D platform and clinical data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TLSA-Tiziana-Life-Sciences&v=1772696281905 "A chart showing the difference between the consensus forecast and the actual stock price. TLSA (Tiziana Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Tiziana (TLSA) is a biotech company developing innovative drug delivery methods (such as a nasal spray) to treat autoimmune diseases such as multiple sclerosis. This chart shows general expectations for the immunopharma sector, reflecting whether experts believe R&D success in this complex field is possible.
Analysts' consensus forecast for the overall market share price
Tiziana Life Sciences is a biotech company developing drugs (including nasal therapies) for the treatment of immune and neurological diseases, such as multiple sclerosis. This chart shows the overall risk appetite. For Tiziana, a clinical-stage company with innovative delivery methods, overall market optimism is important for raising capital for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tiziana Life Sciences
Tiziana is a biotech company betting on nasal delivery. They're trying to treat autoimmune and neurological diseases (multiple sclerosis) by delivering antibodies (Foralumab) through the nose to retrain the immune system. This graph is a clear indicator of their faith in R&D. It reflects their progress in clinical trials and their confidence in their non-invasive platform.
AKIMA Market Segment Index - Pharma immune
Tiziana Life Sciences is a biotech company developing innovative treatments for immune and inflammatory diseases, including a nasal spray for COVID-19 and multiple sclerosis. This chart shows the average index for the immunology sector. It helps assess how promising Tiziana's platform is compared to the industry average.
The AKIM Index for the overall market
Tiziana Life Sciences is a biotech company developing immunomodulatory therapies (nasal antibodies) for the treatment of multiple sclerosis and Alzheimer's disease. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
